Effects of hop compounds on the immune system in overweight individuals
Effect of Iso-alpha Acids and Xanthohumol on the Human Immune System in Overweight People With the Onset of Metabolic Diseases
This study tests whether compounds from hops can help boost the immune system in overweight people who might be at risk for metabolic diseases.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 24 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | University of Vienna Academic / other |
| Locations | 1 site (Vienna) |
| Trial ID | NCT06745102 on ClinicalTrials.gov |
What this trial studies
This study investigates the impact of Xanthohumol and Iso-alpha Acids, derived from hops, on the immune response in overweight participants who may have incipient metabolic diseases. Participants will consume a study drink containing these compounds along with a light breakfast, followed by multiple blood samples taken over several hours to assess various clinical parameters and inflammatory markers. The goal is to determine the protective effects of these compounds on isolated blood cells and how they differ from those in normal-weight individuals.
Who should consider this trial
Good fit: Ideal candidates are overweight individuals with a BMI between 25 and 29.9 who also have pre-diabetes, fatty liver, or mild hypertension.
Not a fit: Patients with a history of gastrointestinal diseases, kidney or liver disease (other than simple fatty liver), or those on special diets may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into dietary interventions that enhance immune function in overweight individuals at risk for metabolic diseases.
How similar studies have performed: While the specific combination of Xanthohumol and Iso-alpha Acids has not been extensively tested, similar studies on dietary compounds and immune response have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * BMI 25 - 29,9 kg/m² as well as one or more of the following incipient metabolic diseases: * pre-diabetes (fasting blood glucose 100-125 mg/dL), * fatty liver (grade 1-3), * high-normal blood pressure to mild hypertension (grade 1, systolic 140-159 mmHg) Exclusion Criteria: * History of diseases that could falsify the study results * inflammatory bowel diseases * malignant diseases of the gastrointestinal tract * food allergies * malabsorption * kidney or liver disease (except simple fatty liver) * symptomatic heart failure * Taking medication to treat these diseases * Consumption of special diets (e.g. vegan, gluten-free) * Pregnancy
Where this trial is running
Vienna
- University of Vienna — Vienna, Austria (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.